Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. UTHR
stocks logo

UTHR

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
818.74M
+11.26%
6.878
+11.12%
817.94M
+2.96%
7.017
+5.83%
847.01M
+6.06%
7.207
+12.43%
Estimates Revision
The market is revising Downward the revenue expectations for United Therapeutics Corporation (UTHR) for FY2025, with the revenue forecasts being adjusted by -0.26% over the past three months. During the same period, the stock price has changed by 20.87%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.26%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+2.33%
In Past 3 Month
Stock Price
Go Up
up Image
+20.87%
In Past 3 Month
Wall Street analysts forecast UTHR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for UTHR is 520.00 USD with a low forecast of 423.00 USD and a high forecast of 600.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
Wall Street analysts forecast UTHR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for UTHR is 520.00 USD with a low forecast of 423.00 USD and a high forecast of 600.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
4 Hold
0 Sell
Moderate Buy
Current: 484.100
sliders
Low
423.00
Averages
520.00
High
600.00
Current: 484.100
sliders
Low
423.00
Averages
520.00
High
600.00
UBS
Buy
maintain
$580 -> $600
2025-11-06
Reason
UBS
Price Target
$580 -> $600
2025-11-06
maintain
Buy
Reason
UBS raised the firm's price target on United Therapeutics to $600 from $580 and keeps a Buy rating on the shares.
Morgan Stanley
Equal Weight
maintain
$435 -> $447
2025-10-30
Reason
Morgan Stanley
Price Target
$435 -> $447
2025-10-30
maintain
Equal Weight
Reason
Morgan Stanley raised the firm's price target on United Therapeutics to $447 from $435 and keeps an Equal Weight rating on the shares. Despite a Q3 miss, shares traded up following commentary on the call regarding the potential for a Tyvaso rest-of-the-world partnerships following recent Phase 3 IPF data, the analyst noted. During the post Q3 follow up call, management noted that the commentary was meant to suggest that the company is open to partnerships and collaborations, but that there are no active discussions, the analyst tells investors.
RBC Capital
Lisa Walter
Outperform
maintain
$569 -> $587
2025-10-30
Reason
RBC Capital
Lisa Walter
Price Target
$569 -> $587
2025-10-30
maintain
Outperform
Reason
RBC Capital analyst Lisa Walter raised the firm's price target on United Therapeutics to $587 from $569 and keeps an Outperform rating on the shares. The company's Q3 results support the firm's view that Tyvaso will continue to grow irrespective of new market entrants, IPF could double the top-line to over $6B in the next 5 years, and the base business will show resiliency, the analyst tells investors in a research note.
H.C. Wainwright
Andrew Fein
Buy
maintain
$500 -> $525
2025-10-30
Reason
H.C. Wainwright
Andrew Fein
Price Target
$500 -> $525
2025-10-30
maintain
Buy
Reason
H.C. Wainwright analyst Andrew Fein raised the firm's price target on United Therapeutics to $525 from $500 and keeps a Buy rating on the shares following the Q3 report. The firm cites Tyvaso revenue growth and the "strong" early launch of Yutrepia for the target boost.
Jefferies
Roger Song
Buy
maintain
$564 -> $575
2025-10-29
Reason
Jefferies
Roger Song
Price Target
$564 -> $575
2025-10-29
maintain
Buy
Reason
Jefferies analyst Roger Song raised the firm's price target on United Therapeutics to $575 from $564 and keeps a Buy rating on the shares. The firm notes the company put out another revenue record quarter, with Tyvaso as key driver. Also, the company is open to various partnerships such as ex-U.S. for Tyvaso and relinepag with potential to combo with other MOA including Winrevair. Overall, Jefferies believes the set-up is even stronger following the quarter.
UBS
Buy
maintain
$560 -> $580
2025-09-29
Reason
UBS
Price Target
$560 -> $580
2025-09-29
maintain
Buy
Reason
UBS raised the firm's price target on United Therapeutics to $580 from $560 and keeps a Buy rating on the shares. The Tyvaso IPF data from the TETON-2 study could drive a positive stock reaction as the best-in-class efficacy and safety was re-confirmed, the analyst tells investors in a research note.
See All Ratings

Valuation Metrics

The current forward P/E ratio for United Therapeutics Corp (UTHR.O) is 16.92, compared to its 5-year average forward P/E of 12.31. For a more detailed relative valuation and DCF analysis to assess United Therapeutics Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Strongly Overvalued
5Y Average PE
12.31
Current PE
16.92
Overvalued PE
14.18
Undervalued PE
10.44

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
6.62
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
8.05
Undervalued EV/EBITDA
5.20

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4.76
Current PS
0.00
Overvalued PS
5.34
Undervalued PS
4.19
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

UTHR News & Events

Events Timeline

(ET)
2025-11-03
07:16:16
United Therapeutics Reports First Clinical Xenotransplantation in EXPAND Study
select
2025-10-29 (ET)
2025-10-29
06:35:10
United Therapeutics Announces Q3 Earnings Per Share of $7.16, Exceeding Consensus Estimate of $6.96
select
2025-10-28 (ET)
2025-10-28
20:25:00
Major companies set to report ahead of tomorrow's market opening
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
6.5
12-02Barron's
Younger Investors Continue to Favor Sustainable Investing: Insights from an Expert's Selections.

  • Peter Krull's Background: Peter Krull is a financial advisor and director of sustainable investing at Earth Equity Advisors, with over 20 years of experience in sustainable investing.

  • Investment Focus: The firm focuses on sectors like infrastructure, biotechnology, semiconductor manufacturing, and electric vehicles for sustainable investment opportunities.

  • Performance of Green Sage Portfolio: As of September 30, the Green Sage Sustainability Portfolio achieved a return of nearly 14.1%, after accounting for fees.

  • Location: Krull operates from Asheville, North Carolina, where he advocates for sustainable investment practices.

[object Object]
Preview
8.0
11-26NASDAQ.COM
Significant Options Activity on Tuesday: UTHR, GOOGL, META

  • Alphabet Inc Options Trading: Alphabet Inc (GOOGL) experienced a significant options trading volume of 1.1 million contracts, equating to about 245.9% of its average daily trading volume, with notable activity in the $330 strike call option expiring on November 28, 2025.

  • Meta Platforms Inc Options Trading: Meta Platforms Inc (META) also saw high options trading volume of 675,200 contracts, representing approximately 245.9% of its average daily trading volume, particularly in the $630 strike call option expiring on November 28, 2025.

  • Comparison of Trading Volumes: Both GOOGL and META exhibited trading volumes well above their respective averages, indicating heightened investor interest in their options.

  • Further Information: For more details on available expirations for GOOGL, META, or UTHR options, StockOptionsChannel.com provides additional resources.

[object Object]
Preview
3.0
11-23Yahoo Finance
Reevaluating United Therapeutics (UTHR) Valuation Following Significant Share Price Increases

  • Stock Performance: United Therapeutics (UTHR) has experienced a 13% increase in stock price over the past month and a 31.8% gain year-to-date, reflecting strong revenue and net income growth.

  • Valuation Insights: Analysts suggest a fair value of $513 for UTHR, indicating it may be undervalued at its recent closing price of $474.82, driven by robust fundamentals and ambitious growth strategies.

  • Innovation Pipeline: The company is focusing on advanced clinical studies and technologies, including progressive fibrosis treatments and organ manufacturing, which could lead to new revenue streams in personalized and regenerative medicine.

  • Investment Risks: Despite positive growth expectations, potential competitive threats and clinical setbacks could impact future performance, highlighting the need for cautious investment considerations.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is United Therapeutics Corp (UTHR) stock price today?

The current price of UTHR is 484.1 USD — it has increased 0.65 % in the last trading day.

arrow icon

What is United Therapeutics Corp (UTHR)'s business?

United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.

arrow icon

What is the price predicton of UTHR Stock?

Wall Street analysts forecast UTHR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for UTHR is 520.00 USD with a low forecast of 423.00 USD and a high forecast of 600.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is United Therapeutics Corp (UTHR)'s revenue for the last quarter?

United Therapeutics Corp revenue for the last quarter amounts to 799.50M USD, increased 6.76 % YoY.

arrow icon

What is United Therapeutics Corp (UTHR)'s earnings per share (EPS) for the last quarter?

United Therapeutics Corp. EPS for the last quarter amounts to 7.16 USD, increased 12.05 % YoY.

arrow icon

What changes have occurred in the market's expectations for United Therapeutics Corp (UTHR)'s fundamentals?

The market is revising Downward the revenue expectations for United Therapeutics Corporation (UTHR) for FY2025, with the revenue forecasts being adjusted by -0.26% over the past three months. During the same period, the stock price has changed by 20.87%.
arrow icon

How many employees does United Therapeutics Corp (UTHR). have?

United Therapeutics Corp (UTHR) has 1305 emplpoyees as of December 05 2025.

arrow icon

What is United Therapeutics Corp (UTHR) market cap?

Today UTHR has the market capitalization of 20.84B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free